Eli Lilly: FDA approves Retevmo
(CercleFinance.com) - Eli Lilly has announced that the US FDA has approved Retevmo (selpercatinib, 40 mg and 80 mg capsules) for certain adult patients with locally advanced or metastatic solid tumors with a positive RET fusion.
"In the LIBRETTO-001 trial, selpercatinib demonstrated clinically meaningful and durable responses across a variety of tumor types in patients with RET-driven cancers, including pancreatic, colon and other cancers in need of new treatment options," said Vivek Subbiah, associate professor of Investigational Cancer Therapeutics at The University of Texas.
"These data and FDA approval of the tumor-agnostic indication underscore the importance of routine, comprehensive genomic testing for patients across a wide variety of tumor types," he added.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
"In the LIBRETTO-001 trial, selpercatinib demonstrated clinically meaningful and durable responses across a variety of tumor types in patients with RET-driven cancers, including pancreatic, colon and other cancers in need of new treatment options," said Vivek Subbiah, associate professor of Investigational Cancer Therapeutics at The University of Texas.
"These data and FDA approval of the tumor-agnostic indication underscore the importance of routine, comprehensive genomic testing for patients across a wide variety of tumor types," he added.
Copyright (c) 2022 CercleFinance.com. All rights reserved.